ABSTRACT
INTRODUCTION
Bioluminescent proteins are gaining increased importance in detection and quantitation of biological substances, due to their high sensitivity and the high rate at which assays can be performed. However, the wild-type Photinus pyralis luciferase is unstable, which has hindered its use in immunoassays. Recently, the complete nucleotide sequence of the structural gene for stable luciferase of the marine ostracod crustacean Vargula hilgendorfii (4, 8) (formerly known as Cypridina hilgendorfii) has been determined (16) . This has enabled us to consider this gene as a candidate for obtaining a bifunctional immunoreagent. The primary structure consists of a single polypeptide chain of 555 amino acids with two potential glycosylation sites. We have employed this enzyme for the following reasons: ( i)The enzyme is infinitely stable at room temperature in a dried state.
( ii) The light-emitting reaction is very simple, consisting of the oxidation of luciferin by molecular oxygen in the presence of Vargula luciferase; the reaction also does not involve energy-rich compounds like ATP (15, 20) . ( iii)Product inhibition is not observed.
As the second moiety for conjugation, we have used the well-documented protein A of Staphylococcus aureus (22) , which binds to the Fc region of various mammalian IgGs. Protein A has five homologous domains (E, D, A, B and C), and we have utilized the D domain (SpA-D) for our construction of the chimeric protein. Since chemical conjugation often results in loss of enzyme activity and a decrease in yield due to the formation of unexpected homodimers, we have conjugated the two moieties at the gene level, thus obtaining a stoichiometrically controlled product. Such chimeric proteins should retain their bifunctional properties and hence be useful for immunoassays that rely on both binding properties and enzymatic activity for the sensitive detection of antigen or antibody. In this paper we demonstrate how we successfully obtained a chimeric protein having both antibody binding and luminescent properties, by the introduction of a peptide link between the two moieties. The bipartite protein seems promising for use in sensitive immunoassays.
MATERIALS AND METHODS
Oligonucleotides were synthesized using an Applied Biosystems automated DNA synthesizer (Tokyo, Japan). All amplifications of DNA were done using Pyrococcus furiosus(pfu) DNA polymerase obtained from Stratagene (La Jolla, CA, USA). Polymerase chain reaction (PCR) was performed in a DNA Thermal Cycler from PerkinElmer (Takara, Tokyo, Japan). The strain of Escherichia coli used for propagation of DNA was XL1-Blue (Stratagene). Luciferin was chemically synthesized in accordance with the method of Inoue et al. (7) . All other enzymes were from Takara (Tokyo, Japan) and New England Biolabs (Beverly, MA, USA). The chemicals and other reagents were obtained from Sigma Chemical (St. Louis, MO, USA) and Kanto Chemicals (Tokyo, Japan).
Gene Construction
Expression plasmids were constructed by standard techniques (14 4 , 0.1% Triton ® X-100, 10 ng/ µ L nuclease-free bovine serum albumin (BSA) and 2.5 units pfuDNA polymerase in 100 µ L reaction mixture were used for PCR performed in a DNA Thermal Cycler. All PCR were carried out for 30 cycles of denaturation (1 min at 94°C), annealing (1 min at 55°C) and extension (2 min at 72°C). The amplified fragment digested with Pst I was inserted into Pst I-digested pUC-type vector pTV118N (Takara) into which had been inserted a 574-bp Nco I fragment of pRSVVµ ERCA (21) containing mouse V NP signal sequence at its Nco I site. The recombinant with the correct orientation was selected by restriction analysis and nucleotide sequencing using Sequenase ® (United States Biochemical, Cleveland, OH, USA) and was confirmed as the D domain of protein A. This plasmid was digested with Nco I and Afl II to get a fragment of SpA-D that has V NP Ig signal sequence at its 5 ′ end and a splice donor sequence at its 3 ′ end. The purified fragment was ligated with Nco IAfl II-digested pRSVVµ ERCA of which the Nco I site in the simian virus 40 (SV40) early promoter region had been removed with T4 DNA polymerase and denoted pRSVPAER. To insert luciferase into this, the intron between mouse IgM CH2 and CH3 with splicing consensus sequence was amplified by PCR using primers 5 ′ -GTCTTAAGTAGGTT T GGGGG-3 ′ and 5 ′ -GACCTGCAGGCAAGAGA-ACACTGTG-3 ′ that contained the Afl II and Sse8387I restriction sites, respectively, and plasmid pRSVVµ ERCA as template. The 1.58-kbp Vargulaluciferase fragment was obtained by PCR using 5 ′ -TGCCTGCAGGTCCGTCA-AGTACACCAACAG-3 ′ (otherwise called cluc back) and 5 ′ -ACGCGGC -CGCTTATTGGCA TTCAGGT GGTA-3 ′ having Sse 8387I and Not I sites, respectively, as primers, and pSTCL81 plasmid (Kazami et al., unpublished) having the entire cDNA as the template DNA. The PCR conditions and the buffer constituents were the same as for the amplification of the SpA-D-encoding fragment. Restriction endonuclease-digested PCR fragments were ligated subsequently to pRSVPAER at sites Afl II and Not I (modified the unique Xba I site with Not I linker), excising the EGFR fragment to yield the final construct-pRSVPAcluc having both SpA-D and luciferase coding regions, via intron, which would enable rapid exchange of exons. The expression plasmid pRSVPALcluc with linker (Gly) 4 Ser between SpA-D and luciferase was constructed as above, but using primer 5 ′ -CCTGCAGGCGGTG-GCGGA TCGCCGTCAAGTACAC -CA-3 ′ instead of cluc back. For the expression of wild-type luciferase in mammalian cells, a 1.6-kbp Asp 718 fragment of the entire luciferase cDNA in pSTCL81 with its own secretion signal was introduced into expression plasmid pcDNA III (Invitrogen, San Diego, CA, USA) at the Asp 718 site in the desired orientation, resulting in plasmid pccluc.
Expression in Mammalian Cells
The simian COS-1 cell (Riken Cell Bank, Tokyo, Japan) was transfected with gel-filtrated plasmids by the DEAE-dextran method. The cells were cultured using Dulbecco's minimum essential medium (Nissui Pharmaceutical, Tokyo, Japan) containing 10% calf serum (Life Technologies, Gaithersburg, MD, USA) in a humidified 5% CO 2 incubator at 37°C. After 4 to 5 days of incubation, the culture supernatant and the adherent cells were collected for luciferase activity measurement. Stable transfectants of Vargula luciferase were obtained from dihydrofolate reductase-deficient CHO cells (CRL-9096; ATCC, Rockville, MD, USA) by cotransfection with 20 and 2 µ g of pRSVPALcluc and pSV2dhfr (23) , respectively, by the method of Chen and Okayama (3). The transfectants that had survived the nucleotidefree α -MEM (Life Technologies) were amplified with increasing concentration of methotrexate from 0.020 to 1 µ M.
Assay for Luciferase Activity
The luciferase activity of the chimeric protein secreted in the culture medium as well as that of cytosolic extract was measured with an ATP photometer (Sai Technology, CA, USA) standardized with a [ 14 C] 1-hexadecane light source (5). The cytosolic extract was prepared in 1 mL of phosphatebuffered saline (PBS, pH 7.2), after sonicating cells with sonifier [Branson, Danbury, CT, USA] in the presence of protease inhibitors, leupeptin and aprotinin (5 µ g/mL each). Two microliters of 0.1 µ g/mL luciferin were added per reaction volume, immediately before bioluminescent activity measurement.
Protein Characterization and Western Blot Analysis
The chimeric proteins obtained after transfection of COS-1 cells with plasmids pRSVPAcluc and pRSVPALcluc were each analyzed for luciferase activity. The IgG binding ability of the chimeric protein was primarily examined by measuring the luminescent activity of the Sepharose-bound luciferase after incubation of 300 µ L of culture supernatant containing the chimeric protein with 20 µ L of human IgG-Sepharose 6FF (Pharmacia Biotech, Uppsala, Sweden) for 1 h at 4°C on a rotating wheel after removal of the unbound chimeric protein with PBS.
For confirmation of the expression of the chimeric SpA-D-luciferase, Western blotting was performed as follows: The cytosolic extract was prepared by lysing about 8 × 10 5 cells with 100 µ L of PBS containing 1% Triton X-100, and 10 µ L of the above extract were taken. The proteins were resolved by 7.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel electophoresis [as described by Laemmli (9) ] and transferred overnight to nitrocellulose (18) , blocked with 3% locally available skimmed milk in TBST (50 mM TrisHCl, 150 mM NaCl, pH 7.2, containing 0.1% Tween 20) . The filter was incubated serially with rabbit anti-luciferase antiserum (raised against recombinant Vargula luciferase) and peroxidase-conjugated goat anti-rabbit antibody (Tago, Burlingame, CA, USA) in TBST.
The chimeric proteins secreted in the culture supernatant as well as those of cytosolic extract were further analyzed for its IgG binding ability as follows: The Sepharose-bound protein was eluted with 1 mL of 0.1 M acetate buffer of pH 3.3, precipitated by the addition of 150 µ L of 20% trichloroacetic acid, centrifuged and electrophoresed as above. The IgG binding ability was evaluated by incubating the filter with peroxidase-conjugated rabbit IgG (The Binding Site, Birmingham, UK) in TBST. All blots were visualized by enhanced chemiluminescent detection system (Amersham International, Little Chalfont, Bucks, UK) for peroxidaselabeled antibodies.
Immuno-Luminometric Assay Using the Chimeric Protein
Standard curve for human IgG was determined as follows: Various amounts of IgG-Sepharose 6FF were taken, and the volume of the dispersed beads were adjusted to 20 µ L with Sepharose 6B. These beads were incubated with 300 µ L of the culture supernatant containing chimeric protein at 4°C on a rotating wheel for 1 h. The beads were washed 4 to 5 times with 1 mL PBS to wash out the unbound (SpA-D-luciferase) protein. The bioluminescent activity of luciferase bound to the beads was measured after dispersing the beads in 500 µ L of PBS and injecting luciferin just before measurement as described above.
For sandwich ELISA format, monoclonal anti-trinitrophenol (TNP) mouse antibody 2E3 (IgG 1 ) was assayed (10) . To obtain TNP-Sepharose, 1 mg/mL of sodium salts of trinitrobenzene sulfonate (Wako, Osaka, Japan) was conjugated to EAH-Sepharose 4B (Pharmacia Biotech) in 2% sodium borate buffer for 1 h at 20°C. Twenty microliters of TNP-Sepharose were taken, and 0 to 2 µ L of 1 µ g/ µ L 2E3 antibody in 1 mL of PBS were incubated for 1 h at 4°C on a rotating wheel. Subsequently, 10 µ g/mL rabbit anti-mouse IgG (Zymed, San Francisco, CA, USA) was similarly incubated in 1 mL PBS. The amount of rabbit IgG bound to Sepharose by 2E3 antibody was assayed after incubating 300 µ L of the culture supernatant containing the chimeric protein for additional 1 h.
RESULTS

Plasmid Construction
The expression vector, pRSVPAcluc consists of the gene coding for Vargula luciferase fused at the 3 ′ -end of the D domain of protein A (SpA-D). Figure 1 shows a schematic structure of the vector pRSVPALcluc that has a linker of 5 amino acids inserted between SpA-D and luciferase.
Protein Expression and Characterization
When the COS-1 cell was transfected with plasmid pRSVPAcluc, bioluminescent analysis of the chimeric protein indicated that there was significant activity of luciferase both in the cell extract as well as in the culture supernatant when compared to that of mocktransfected cells. The results suggest that the expression of the chimeric protein in the COS-1 cell was successful and that the light-emitting property of luciferase was retained, even when conjugated with SpA-D. To confirm this, Western blot analysis of this chimeric protein using rabbit polyclonal antibody raised against V. hilgendorfii luciferase was performed. The main band was observed as shown in Figure 2 (lane 1) of about 76 kDa as expected from comparison with that of luciferase alone (lane 4) (about 68 kDa), thus confirming that luciferase was fused to SpA-D. The variation in molecular weight of the chimeric protein from that of the calculated weight (67.973 kDa) may be due to the posttranslational modifications. The IgG binding ability of the chimeric protein was then investigated. The culture supernatant of cells transfected with pRSVPAcluc was incubated with IgG-Sepharose 6FF for 1 h. After repeated washings of the Sepharose beads to remove the unbound chimeric protein, the addition of luciferin showed no rise in photon counts and hence no luciferase activity could be observed. This indicated that the binding affinity of the chimeric protein to the Fc region of IgG is either lost or reduced considerably.
So that the properties of protein A could be restored, we introduced a linker between SpA-D and luciferase. We have chosen the amino acid sequence of the linker as GlyGlyGlyGlySer, derived from those used to connect heavy-and light-chain variable domain in single-chain antigen-binding proteins (6) . We have selected this particular linker because it contains no basic residues that could be degraded by protease, and in addition, glycine residues have more conformational freedom than any other amino acid. The new protein was transiently expressed in the COS-1 cell. After observing that there was significant luciferase activity of the secreted chimeric protein as compared with mock-transfected culture medium, the IgG binding capability of the chimeric protein was examined. We found that the new chimeric protein bound to IgG-Sepharose, as evidenced from bioluminescent measurement of the Sepharose-bound chimeric protein. The cytosolic extract was electrophoresed on SDS polyacrylamide gel, blotted onto nitrocellulose paper and probed with anti-luciferase antibody, when a distinct band of molecular weight similar to that without linker was observed as seen in Figure 2 (lanes 1 and 2) .
To further confirm the ability of SpA-D to bind to human and/or rabbit IgG, Western blot analysis with preimmune IgG was carried out. The cytosolic extract and the culture supernatants, purified with human IgG-Sepharose, were electrophoresed and transferred to nitrocellulose. Analysis of pRSVPAcluc-transfected cells using rabbit IgG peroxidase produced no desired band, confirming that the binding activity of SpA-D to human IgG had diminished although the luciferase activity could be retained. In contrast, cells transfected with pRSVPALcluc showed a distinct band in both the cytosolic extract and the culture supernatant (data not shown).
In order to obtain a stable transfectant, pRSVPALcluc plasmid was transfected into Chinese hamster ovary (CHO) cells. The cytosolic extract of the transfectants exhibited a distinct band of about 76 kDa (Figure 2 , lane 5). The chimeric protein secreted in the culture medium was found to be of slightly higher molecular weight than those of cytosolic protein in both COS-1 and CHO cells (lanes 6 and 7) . There was no apparent proteolytic product, indicating that the chimeric protein was not susceptible to proteolytic degradation in culture supernatants nor under further treatments. Quantitation of the protein was performed by blot analysis, by comparison with that of known amounts of purified luciferase protein produced in yeast (13) . The amount of the chimeric protein thus obtained in CHO cells after amplification with methotrexate, was estimated to be about 300 µ g/L of culture supernatant.
To find out the specific activity of the chimeric protein, plasmid pccluc encoding the entire cDNA of Vargula luciferase with its own secretion signal in an expression vector pcDNA III having human cytomegalovirus promoter was constructed. The comparison of the bioluminescent activity of the chimeric luciferase with that of non-fused protein indicated that the specific activity of the chimeric luciferase was 50% (data not shown). This could be explained by a minor distortion in the native conformation of luciferase due to the fusion of protein A or some steric hinderance around the active site. However, the pH dependence and the thermal stability of the chimeric protein were almost the same as those of the native luciferase (data not shown), which indicates that the fusion to SpA-D did not significantly alter its characteristics.
To assess the bifunctionality and hence the applicability of the chimeric SpA-D-luciferase protein, we performed a number of immunoassays. Figure 3 illustrates the quantitative measurement of luciferase activity by incubating different amounts of human IgG-Sepharose with the chimeric protein. A linear relationship between the amount of human IgG covalently immobilized on Sepharose and the bioluminescent activity was observed. Using these beads, we could measure the bioluminescent activity up to the minimum concentration of 10 -9 g/mL of human immunoglobulin.
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DISCUSSION
Luminometric assays are known to be speedy and highly sensitive. In this paper, we have constructed a bifunctional chimeric protein by gene fusion using highly stable luciferase of V. hilgendorfii as one of the moieties. It is possible to semipermanently preserve the luminescent activity of Vargulaluciferase protein in dehydrated condition (4). The enzyme has 34 cysteine residues that may contribute to the stability of the protein. Vargulaluciferase catalyses the light-emitting reaction over a broad pH range with an optimum pH near 7.2 (2). Such unique properties of the luciferase have aroused our interest in designing a chimeric protein for diagnostic purposes. Mammalian cells, COS-1 and CHO cells are known to be functional hosts for luciferase production (17) , but the expression of luciferase in E. coliusing the pel B signal peptide-mediated secretion system (11) was not possible presumably due to the cysteine-rich characteristics of luciferase that might have impeded proper folding of luciferase.
We have chosen the monodomain of protein A as the other moiety of the chimeric protein. SpA-D having 61 amino acid residues is 78.9% homologous to the widely studied B domain. Incidently, SpA-D domain is 90.2% homologous to the recently reported synthetic composite immunoglobulin binder (SCIB) gene encoding a single IgG Fc binding domain (19) . Significant luciferase activity was observed in the cytosolic extract and in the culture supernatant, when the chimeric protein was expressed using plasmid pRSVPAcluc in COS-1 cells. However, we found that this chimeric protein which does not possess a linker between SpA-D and luciferase had diminished IgG binding activity. The insertion of a linker of five amino acids could enable the Fc binding ability of protein A to be retained, and hence, SpA-D could be considered as a new functional domain of protein A, similar to SCIB (19) . The retention of the IgG binding activity may be considered due to the restoration of the wild-type conformation of SpA-D required for efficient binding. It may be configured from the fact that the SpA-D domain loses its binding capability without the linker and that the conformation of the carboxy(C)-terminal region may be responsible for the overall stability of SpA-D, although not directly involved in the binding to the Fc region of IgG. During the preparation of this manuscript, Bottomley et al. (1) indicated that the third αhelix, which is the C-terminal region of the B domain of protein A, contributes to the overall stability of the domain and to the formation of the IgG binding site in the first and second αhelix. So we may conclude from our experiment that the linker between SpA-D and luciferase aids in proper conformation of the Cterminal region of SpA-D, which in turn leads to higher affinity for the Fc region. Further lengthening of the linker motif to 15 amino acids (GlyGlyGlyGlySer) 3 did not alter the functional significance of both the moieties (data not shown).
Our purpose in constructing this chimeric protein was to evaluate its feasibility in immunoassays. Since the protein is efficiently secreted from the cells into the medium, we could directly use the culture medium containing the fusion protein for preliminary testing in immunoassays. A calibration curve was drawn for human IgG bound to Sepharose as shown in Figure 3 and an estimation of the detection limit for human IgG was approximately 10 -10 M. The chimeric protein was further evaluated by performing a sandwich assay for the quantitation of anti-TNP antibodies. It can be deduced from the activity of luciferase that the chimeric protein was specifically bound to antibody molecules and that no background signal was produced by nonspecific binding to other components.
In summary, we have successfully produced a chimeric protein possessing both the luminescent activity and antibody binding properties, which would be useful in detecting trace amounts of antibody or antigen in a simplified and rapid reaction.
